Gene editing site determination is the core molecular characterization step required to confirm and document the precise genomic modifications introduced into new plant, animal, and microbial varieties developed with CRISPR/Cas, base editors, TALEN, and other targeted nucleases. Accurate identification of on-target edits, screening of off-target events, and verification of the absence of residual transgene integration are essential for regulatory submission, breeding decisions, and intellectual property protection. This article explains the technical scope, sample requirements, testing items, analytical methods, and typical applications of gene editing site determination services offered by accredited third-party laboratories.
Technical Overview
Gene editing site determination refers to the systematic molecular characterization of the specific genomic loci modified in a new variety created through targeted genome engineering. Modern new varieties are typically developed using site-directed nucleases such as CRISPR/Cas9, CRISPR/Cas12a, cytosine and adenine base editors, prime editors, TALEN, and zinc-finger nucleases. Because regulatory authorities worldwide increasingly distinguish genome-edited organisms from conventional transgenic organisms, developers must provide precise sequence-level evidence of what was changed, where the change occurred, and whether any unintended modifications exist elsewhere in the genome.
The characterization process generally addresses four questions: first, whether the intended edit was successfully introduced at the target locus; second, what the exact edited sequence looks like, including the nature of insertions, deletions, and substitutions and the allelic composition of the organism; third, whether unintended edits occurred at off-target sites that share sequence homology with the guide RNA or nuclease binding site; and fourth, whether any foreign DNA, such as the nuclease expression cassette or selectable marker, remains integrated in the genome. The resulting data support the classification of the variety into edit categories such as SDN-1 (small insertions or deletions without a repair template), SDN-2 (template-directed small modifications), and SDN-3 (larger insertions), which is a key determinant of the applicable regulatory pathway in many jurisdictions.
Testing is performed by accredited third-party laboratories operating under ISO/IEC 17025 quality management systems, with analytical concepts aligned with the ISO 24276 series of general requirements for the analysis of genetically modified organisms, ISO 21571 for nucleic acid extraction, OECD consensus guidance on the molecular characterization of novel plants, and relevant GB/T national standards for molecular detection where applicable.
Testing Samples
Plant Materials
Seeds, seedlings, young leaves, callus tissue, embryos, and floral tissues from edited crops such as rice, wheat, maize, soybean, tomato, rapeseed, cotton, and vegetables are the most common sample types. Genomic DNA is extracted from these matrices, and the target region is amplified and sequenced. Fresh or frozen leaf tissue is generally preferred because it yields high-molecular-weight DNA suitable for both short-read and long-read analysis.
Animal Materials
For gene-edited livestock, aquatic species, and model organisms, accepted samples include ear notches, blood, hair follicles, tissue biopsies, semen, and embryos. These matrices allow confirmation of the edited allele, zygosity determination, and screening for off-target events in founder animals and their offspring.
Microbial and Cell Line Materials
Edited bacterial strains, fungal strains, yeast, and engineered mammalian cell clones can be submitted as fresh cultures, glycerol stocks, pelleted cells, or purified genomic DNA. Characterization of these samples focuses on edit confirmation at the target locus, screening for unintended modifications, and verification of plasmid or cassette removal where a clean, transgene-free clone is required.
Segregating and Derived Materials
Advanced breeding materials such as F1 and F2 segregating populations, backcross lines, and near-isogenic lines are tested to track the inheritance of the edited allele, confirm homozygosity, and demonstrate that the nuclease transgene has been segregated away from the edit, which is frequently a prerequisite for regulatory exemption or simplified review.
Sample Requirements
Typical submission requirements include the following considerations, with exact specifications confirmed with the laboratory before shipping:
- Sample quantity: generally 100 mg to 1 g of fresh tissue, 20 to 100 seeds, or 1 to 5 mL of blood depending on the matrix.
- DNA quality: an A260/A280 ratio of approximately 1.8 to 2.0, sufficient concentration, and high integrity, particularly when long-read sequencing is planned.
- Documentation: target gene name, guide RNA or nuclease target sequences, expected edit type, reference genome build, and species information.
- Storage and shipping: samples shipped chilled or frozen with cold packs or dry ice, using sterile, labeled containers to prevent cross-contamination and degradation.
Testing Items
Gene editing site determination is composed of several discrete testing items that together provide a complete molecular characterization of the edited variety:
- On-target edit confirmation: verification that the intended insertion, deletion, base substitution, or segment replacement is present at the designed target site.
- Edited sequence determination: full read-through sequencing of the target region, including both alleles, to document the exact edited sequence and junction regions.
- Genotype and zygosity analysis: classification of individuals as wild type, heterozygous, homozygous, biallelic, or chimeric, with allele-level resolution.
- Editing efficiency quantification: measurement of the proportion of reads carrying each edited allele, reported as an allele frequency or editing rate.
- Large event detection: identification of large fragment deletions, inversions, duplications, and chromosomal translocations that may span regions beyond standard amplicons.
- Off-target site screening: sequencing of computationally predicted candidate off-target loci to detect unintended edits that may have arisen from guide RNA mispairing.
- Transgene integration screening: detection of residual nuclease expression cassettes, guide RNA scaffolds, and selectable marker genes to demonstrate transgene-free status.
- Copy number determination: quantification of inserted sequence copy number by digital PCR or quantitative PCR where insertions are present.
- Donor template insertion characterization: sequencing of homology-directed repair events to confirm precise integration and exclude random backbone insertion.
- Classification support data: generation of the sequence evidence package needed to classify the event as SDN-1, SDN-2, or SDN-3 for regulatory purposes.
Testing Methods
Accredited third-party laboratories apply a tiered methodological strategy that matches the analytical technique to the biological question, the expected edit size, and the required detection sensitivity.
PCR Combined with Sanger Sequencing and Chromatogram Decoding
The target region is amplified by locus-specific PCR and sequenced using the Sanger method. For mixed or heterozygous editing events, chromatogram deconvolution algorithms deconvolute overlapping peaks to reconstruct each allele and estimate their relative frequencies. This approach is fast, cost-effective, and suitable for confirming simple small indels in fixed lines.
Amplicon Deep Sequencing
High-throughput sequencing of pooled target amplicons provides read depths of several thousand to tens of thousands per locus, enabling precise quantification of editing efficiency, detection of rare alleles and low-frequency mosaicism at sensitivities typically below one percent, and complete enumeration of the allele spectrum at the target site.
Long-Read Sequencing
Long-read platforms are used when large deletions, inversions, complex rearrangements, or transgene insertions are suspected, because they can span entire edited regions and repetitive flanking sequences in single reads, resolving structures that short-read amplicons cannot reconstruct.
Whole-Genome Sequing-Based Off-Target Assessment
For comprehensive or unbiased evaluation, whole-genome resequencing of the edited line alongside its isogenic wild-type comparator enables genome-wide variant comparison, capturing both predicted and unpredictable off-target modifications across the entire genome.
In Silico Prediction and Targeted Validation
Bioinformatics off-target prediction tools scan the reference genome for sequences homologous to the guide RNA, ranked by mismatch number and position. The top-ranked candidate sites are then PCR-amplified and deep-sequenced to determine whether unintended edits occurred at each locus.
Digital PCR and Quantitative PCR
These platforms support transgene-free confirmation and support regulatory documentation of event structure.
Bioinformatics and Quality Assurance
Sequencing data are processed through validated pipelines including read quality filtering, alignment to the reference genome, variant calling, allele decomposition, and annotation. Each analytical batch incorporates wild-type controls, no-template controls, positive reference materials where available, and replicate amplification, and key findings from next-generation sequencing are routinely confirmed by independent Sanger verification.
Applications
Gene editing site determination services support stakeholders across the entire variety development and commercialization lifecycle:
- Regulatory dossier preparation: providing the molecular characterization data packages required for the safety evaluation and approval of gene-edited plants, animals, and microorganisms under national regulatory frameworks.
- Breeding pipeline quality control: confirming edits in T0 and subsequent generations, selecting homozygous individuals, tracking allele inheritance, and verifying transgene segregation during line fixation.
- Off-target risk assessment: documenting the absence or presence of unintended edits to inform biosafety evaluation and event selection.
- Intellectual property protection: establishing sequence-level evidence of a specific edited allele for patent filings, plant variety protection applications, and enforcement actions.
- Seed and product identity verification: authenticating edited varieties in seed lots, breeding materials, and commercial products for supply chain integrity.
- Import and export compliance: generating technical documentation demonstrating the edit type and transgene-free status of materials moving across jurisdictions with differing regulatory requirements.
- Research and publication support: supplying rigorous, independently generated sequencing data for peer-reviewed studies and collaborative research programs.
FAQ
What is the difference between on-target and off-target analysis? On-target analysis confirms and characterizes the edit at the intended locus, including the exact sequence change, zygosity, and editing efficiency. Off-target analysis examines other genomic sites with sequence similarity to the guide RNA to determine whether unintended edits occurred elsewhere, using either a candidate-site targeted approach or unbiased whole-genome comparison.
Can the testing confirm that a variety is transgene-free? Yes. Dedicated screening assays detect residual nuclease expression cassettes, guide RNA constructs, and selectable markers. Combined with edit-site sequencing, this provides the evidence needed to demonstrate that the final variety carries the intended edit without integrated foreign DNA.
What detection sensitivity can be achieved? Amplicon deep sequencing typically detects allele frequencies down to approximately 0.1 to 1 percent depending on read depth and background error correction, which is sufficient to identify low-level mosaicism in early-generation plants and founder animals.
How are large deletions and structural changes detected? When deletions or rearrangions exceed standard amplicon size, long-range PCR, long-read sequencing, or whole-genome sequencing is applied to resolve the full structure of the edited region and its junctions.
How long does a typical project take? Simple on-target confirmation by PCR and Sanger sequencing is usually completed within five to ten working days. Amplicon deep sequencing projects generally require ten to fifteen working days, while whole-genome sequencing-based off-target assessments may require several weeks depending on sample number and analysis scope.
What information should be provided when submitting samples? Clients should supply the species and variety name, target gene and locus, guide RNA or nuclease target sequences, expected edit type and size, reference genome version, and any prior sequencing data. This information allows the laboratory to design primers, predict off-target candidates, and select the most appropriate analytical strategy.
Which standards govern this testing? Testing is conducted under ISO/IEC 17025 laboratory competence frameworks, with nucleic acid extraction and analysis concepts aligned to ISO 21571 and the ISO 24276 series, supplemented by OECD molecular characterization guidance and applicable GB/T national standards for molecular detection methods.